Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Mitja Nabergoj*, Diderik Jan Eikema, Linda Koster, Uwe Platzbecker, Katja Sockel, Jürgen Finke, Nicolaus Kröger, Edouard Forcade, Arnon Nagler, Matthias Eder, Johanna Tischer, Annoek E.C. Broers, Jürgen Kuball, Keith M.O. Wilson, Mathilde Hunault-Berger, Matthew Collin, Domenico Russo, Lucía López Corral, Grzegorz Helbig, Alberto MussettiChristof Scheid, Carmelo Gurnari, Kavita Raj, Joanna Drozd-Sokolowska, Ibrahim Yakoub-Agha, Marie Robin, Donal P. McLornan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Therapy-related myeloid neoplasms (t-MN), either myelodysplastic neoplasms (t-MDS) or acute myeloid leukemias (t-AML), have a poor prognosis and allogeneic haematopoietic cell transplantation (allo-HCT) represents the only curative option. In this multicenter, registry-based study, we analyzed outcomes of 378 patients undergoing first allo-HCT between 2006–2017 for t-MN arising secondary to lymphoma treatment. Median age was 58 years at allo-HCT; 222 (59%) had a diagnosis of t-MDS and 156 (41%) of t-AML, respectively. At the time of allo-HCT, 46% of t-MN cases were reported as in complete remission (CR) and 15% of lymphomas were recorded as not in remission. A reduced intensity conditioning regimen was used in 70% of cases. For the entire cohort, 5-year OS, and t-MN PFS, relapse incidence and NRM were 32%, 28%, 35% and 37%, respectively. In multivariable analysis, undergoing allo-HCT with t-MN not in CR and older age were associated with significantly worse OS, PFS and NRM. At 5 years post allo-HCT, the relapse incidence of lymphoma was low at 3%, while the rate of secondary malignancies was 8%. This analysis shows the curative potential of allo-HCT for patients with t-MN arising secondary to lymphoma treatment in approximately a third of patients.

Original languageEnglish
Pages (from-to)395-402
Number of pages8
JournalBone Marrow Transplantation
Volume59
Issue number3
DOIs
StatePublished - Mar 2024
Externally publishedYes

Funding

FundersFunder number
CMWP
EBMT

    Fingerprint

    Dive into the research topics of 'Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT'. Together they form a unique fingerprint.

    Cite this